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ABSTRACT
Purpose To elucidate the chemical modifications in covalent
aggregates of recombinant human insulin induced by metal cata-
lyzed oxidation (MCO).
Methods Insulin was exposed for 3 h at room temperature to
the oxidative system copper(II)/ascorbate. Chemical derivatiza-
tion with 4-(aminomethyl) benzenesulfonic acid (ABS) was per-
formed to detect 3,4-dihydroxyphenylalanine (DOPA)
formation. Electrospray ionization-mass spectrometry (ESI-MS)
was employed to localize the amino acids targeted by oxidation
and the cross-links involved in insulin aggregation. Oxidation at
different pH and temperature was monitored with size exclu-
sion chromatography (SEC) and ESI-MS analysis to further inves-
tigate the chemical mechanism(s), to estimate the aggregates
content and to quantify DOPA in aggregated insulin.
Results The results implicate the formation of DOPA and 2-
amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid
(DOCH), followed by Michael addition, as responsible for new
cross-links resulting in covalent aggregation of insulin during MCO.
Michael addition products were detected between DOCH at
positions B16, B26, A14, and A19, and free amino groups of
the N-terminal amino acids Phe B1 and Gly A1, and side chains of
Lys B29, His B5 and His B10. Fragments originating from peptide
bond hydrolysis were also detected.
Conclusion MCO of insulin leads to covalent aggregation
through cross-linking via Michael addition to tyrosine oxidation
products.
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INTRODUCTION
During pharmaceutical production and storage, therapeutic
proteins can be exposed to components that are able to induce
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metal-catalyzed oxidation (MCO) (1), i.e. redox active transi-
tion metals, peroxides and reductants (2,3). MCO of therapeu-
tic proteins (4) such as recombinant human interferon alfa and
recombinant human interferon beta has been reported to form
highly immunogenic aggregates (5–7), providing evidence that
protein oxidation can potentially lead to severe side reactions
and loss of therapeutic effect. Furthermore, it has been shown
that in diabetic complications (8), copper ion concentrations
are higher than in normal subjects (9). Therefore, MCO is a
potential cause of insulin degradation in vivo as well, when the
production of reactive oxygen species (ROS) exceeds the en-
dogenous antioxidant defense. Montes-Cortes et al. (10) showed
that the carbonyl content of human insulin and the hydroxyl-
ation of phenylalanine, based on the formazan assay (11), is
increased after exposure of insulin to the plasma of diabetic
patients, which can contain high concentrations of oxidants
(12). Moreover, in a recent paper we showed that MCO
induces significant covalent aggregation of insulin in vitro (13).
However, the underlying mechanisms of insulin aggregation
through MCO are still unknown. Previous reports on the
MCO of human insulin and glycated insulin indicate that both
histidine residues are easily oxidized to 2-oxo histidine (2,9).
Here we provide a more detailed analysis of the chemical
modifications that occur during the MCO of recombinant
human insulin, induced by Cu2+ and L-ascorbic acid as a
representative electron donor (14–16), focusing on the amino
acids that are modified and on the chemical mechanisms that
lead to cross-linked insulin, as a consequence of the modifica-
tions in the primary structure. Since previous studies have
demonstrated the presence of DOPA in proteins like catarac-
tous lens proteins (17) and in atherosclerotic lesions (18), em-
phasis was placed on the detection of oxidation products arising
from the four Tyr and the three Phe contained in insulin and,
especially, on the formation of 2-amino-3-(3,4-dioxocyclohexa-
1,5-dien-1-yl) propanoic acid (DOCH), which constitutes a
Michael acceptor for nucleophilic addition. Figure 1, panel a,
displays the primary structure of insulin, the Glu-C digestion
sites, the amino acids (in blue) with nucleophilic function, and
the amino acids (in red) that can be oxidized to 3,4-dihydrox-
yphenylalanine (DOPA) and DOCH; Fig. 1b representatively
illustrates theMichael addition onDOCHat position B16, and
Fig. 1c shows the product of Michael addition on oxidized
insulin. Complementary detection of DOPA and DOCH was
achieved using mass spectrometry and fluorogenic tagging with
4 (aminomethyl)benzene sulfonic acid (ABS) (Scheme 1),
according to the method reported recently by Sharov et al.
(19,20) Our results indicate that all aromatic amino acids of
insulin, i.e. His, Tyr and Phe, are subject to MCO, predomi-
nantly yielding mono- and/or dihydroxylation products (or
their respective oxidation products, i.e. DOCH from DOPA).
Important for the mechanistic analysis of covalent protein
aggregation, we detected cross-links between DOCH at posi-
tions B16, B26, A14, and A19 and free amino groups of the N-
terminal amino acids Phe B1 and Gly A1, and the side chains
of Lys B29, His B5 and His B10.
MATERIALS AND METHODS
Materials
Recombinant human insulin containing 0.4 % (w/w) zinc was
provided by Merck (Oss, The Netherlands). L-ascorbic acid,
ethylenediaminetetraacetic acid sodium salt (EDTA), copper
dichloride, arginine, monobasic and dibasic sodium hydrogen
phosphate, ammonium bicarbonate (ABI), dithiothreitol
(DTT), iodoacetamide (IAM) and the solvents glacial acetic
acid and acetonitrile were purchased from Sigma–Aldrich
(St.Louis, MO, USA). Millipore Q water was used for the
preparation of all the formulations and solutions. All chemicals
were of analytical grade and used without further purification.
ABS was synthesized according to a published procedure (21).
Glu-C endoproteinase used in this study was purchased from
Promega (Madison, WI, USA). Centrifugal filter units with a
volume capacity of 4 mL and a molecular weight cut-off of
3 kDa were purchased from Millipore (Billerica, MA, USA).
Cassette dialysis slides with a 2 kDa cut-off were purchased
from Thermo Scientific (Asheville, NC, USA).
Metal-Catalyzed Oxidation of Insulin
Insulin oxidation was performed at three pH values: pH 7.4 in
50 mM sodium phosphate buffer (PB), pH 3.0 in 50 mM
sodium citrate buffer (CB) and at pH 8.0 in 250 mM ammo-
nium bicarbonate (ABI). For all the oxidation reactions, insulin
was first dissolved in 0.1 M hydrochloric acid and then diluted
into the corresponding buffer. Depending on the desired pH,
0.1 M sodium hydroxide was used. When CB was used, the
final pH of 3 was achieved without further addition of base.
Insulin concentration was measured by UV spectroscopy using
a molecular weight of 5.8 kDa and an extinction coefficient of
6200M−1 cm−1 at 276 nm (22). Further dilutions in PB, ABI or
CB were performed to obtain a final insulin concentration of
1 mg/mL. Controls included 1 mg/mL of insulin in
50 mM PB, pH 7.4; in 50 mM CB, pH 3.0; and in 250 mM
ABI, pH 8.0. MCO was performed by addition to 1 mL of
1 mg/mL insulin, 100 μL of 0.4 mMCuCl2 in 50 mM PB, pH
7.4, or in 50 mM CB, pH 3, or in 250 mM ABI, pH 8,
depending on the desired pH, to a final concentration of
40 μM CuCl2. The reaction was performed in 2-mL Eppen-
dorf tubes covered with aluminum foil to protect the reaction
mixture from light. After 10 min of incubation of insulin with
Cu2+, to allow copper to bind to insulin, the oxidation reaction
was started by the addition of 110 μL of 40mML-ascorbic acid
in 50 mM PB, pH 7.4, or in 50 mM CB, pH 3, or in 250 mM
ABI, pH 8, depending on the desired pH, to a final
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concentration of 4mM.The reaction was quenched after 3 h of
incubation at room temperature by adding 12.1 μL of a
100 mM EDTA in 50 mM PB, pH 7.4, or in 50 mM CB,
pH 3, or in 250 mMABI, pH 8, depending on the desired pH,
to a final concentration of 1 mM (15). To monitor the presence
of protein fragments, the oxidation was also performed (in PB
with the same amount of copper and L-ascorbic acid) at room
temperature and at 37°C for 24 h before quenching. The
oxidized samples were extensively dialyzed at +4°C against
50 mM ammonium bicarbonate (ABI) buffer, pH 8.0, for
24 h. In another experiment, the oxidized sample in 50 mM
sodium citrate buffer pH 3, was extensively dialyzed at+4°C in
50 mM sodium phosphate buffer, pH 7.4, using centrifugal
filter units. After that the sample was left to equilibrate for 12 h
at room temperature.
ABS-Derivatization of Undigested Samples
Solutions of native insulin and insulin oxidized at pH 3.0 (in
CB) and pH7.4 (in PB), dialyzed into 50mMABI, were treated
with 0.1M sodium hydroxide to a final pH of 9.0. Subsequent-
ly, to 100 μL of these solutions, 11 μL of a solution of 100 mM
ABS dissolved in water were added to a final concentration of
10 mM. Next, 1.1 μL of 50 mMK3Fe(CN)6 dissolved in water
Fig. 1 (a) primary structure of
human insulin with the Glu-C
endoproteinase digestion sites. In
blue are shown the nucleophilic
amino acids which can be involved
in Michael addition. In red the
amino acids that can be oxidized to
DOPA and DOCH. (b) Michael
addition on oxidized human insu-
lin. The amino group that initiates a
nucleophilic reaction with the α,β
unsaturated carbonyl compound
(DOCH), represents one of the
nucleophilic amino acids of human
insulin (in blue). (c) Product
of Michael addition
on oxidized insulin.
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was added to a final concentration of 0.5 mM. The reaction
was conducted for 1 h at room temperature before performing
SEC analysis. Controls for non-specific fluorescence included
derivatization reagents (without protein) incubated under the
same conditions and non-derivatized protein.
Reduction, Alkylation and ABS-Derivatization
of Insulin
Solutions of native insulin and oxidized insulin, dialyzed into
50 mMABI, pH 8.0, were reduced using 50 mM dithiothreitol
(DTT), freshly prepared in 50 mM ABI, pH 8.0, added to a
final concentration of 5 mM. The samples were incubated for
45 min at 45°C using a thermo heating bath (Thermo Scien-
tific, Asheville, NC, USA). Subsequently, 200 mM iodoaceta-
mide (IAM), freshly prepared in 50 mM ABI, pH 8.0, was
added to a final concentration of 20 mM. The pH of 100 μL of
dialyzed, reduced and alkylated insulin samples was adjusted to
9.0 with 0.1 M sodium hydroxide. Then, 11 μL of a solution of
100 mM ABS dissolved in water were added to a final concen-
tration of 10 mM. Subsequently, 1.11 μL of 50 mM K3Fe
(CN)6 dissolved in water was added to a final concentration of
0.5 mM. The reaction was conducted for 1 h at room temper-
ature before performing digestion with Glu-C.
Glu-C Digestion
The proteolytic digestion was performed after reduction, al-
kylation and ABS-derivatization of insulin, by incubating the
samples with Glu-C endoproteinase in a ratio insulin: Glu-C
endoproteinase 10:1 (w/w), overnight at 37°C.
Size-Exclusion Chromatography
An Insulin HMWP column (7.8×300 mm, Waters, Milford,
MA, USA) was connected to a Shimadzu HPLC system
(UFLC Shimadzu Instrument equipped with two LC-20AT
pumps, Columbia, MD) coupled to a photo-diode array de-
tector (Shimadzu, SPD-M20A) and a fluorescence detector
(Shimadzu, RF-20A). The photo diode array detector allowed
for the recording of the UV spectrum in the region between
200–800 nm. Undigested insulin samples, without ABS treat-
ment, were injected to calculate the percentages of the aggre-
gates and to measure tyrosine fluorescence. Moreover,
undigested insulin samples that were treated with ABS were
injected to measure the benzoxazole fluorescence, which can
be formed only in presence of DOPA and/or DOCH. The
percentage of aggregates was calculated based on peak areas
of the UV peaks at 276 nm (chromatograms not shown), as
reported by Hermeling et al. (5,6). The fluorescence detector
was set at various different excitation (Ex) and emission (Em)
wavelengths, depending on the type of analysis: Ex 275 nm/
Em 302 nm was used for monitoring Tyr fluorescence and Ex
360/Em 490 nm was used for the detection of the benzox-
azole fluorescence of the ABS-derivatized samples. The mo-
bile phase was composed of a mixture of 1 g/L L-arginine in
water/acetonitrile/glacial acetic acid 65:20:15 (v/v/v) as
reported in the United States and European pharmacopeias
(23,24). The elution buffer was freshly prepared, filtered using
a regenerated cellulose filter (Sartorius Stedim Biotech,
Arvada, CO) and degassed prior to use.
Steady-State Fluorescence Spectroscopy
The benzoxazole fluorescence of the ABS-derivatized samples
was measured upon excitation at 360 nm. The emission
spectra were recorded from 490 nm to 600 nm with a 5-nm
bandwidth on a Shimadzu RF-5000U spectrofluorometer. To
monitor the presence of dityrosine, the non-derivatized, oxi-
dized samples were analyzed after dialysis in 50 mM ABI, pH
8.0, using an excitation wavelength of 315 nm and detection
at 420 nm (25).
Scheme 1 Chemical derivatization of DOPA and DOCH with ABS.
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After ABS-derivatization and dialysis, sample volumes
were diluted with 50 mM ABI to 0.5 mL. Spectra were
recorded in 0.5 mL 1-cm light-pass fluorescence cuvettes
(Hellma, Plainview, NY, USA). Controls for non-specific fluo-
rescence included samples without a substrate or reagents
incubated under the same conditions.
Mass Spectrometry
Digested and non digested peptides were analyzed by means
of an LTQ-FT hybrid linear quadrupole ion trap Fourier
transform ion cyclotron resonance (FT-ICR) mass spectrom-
eter (Thermo-Finnigan, Bremen, Germany) (26) and a
SYNAPT-G2 (Waters Corporation, Milford, MA), both lo-
cated in the Mass Spectrometry Laboratory of the University
of Kansas, under the conditions as described by Ikehata et al.
(26). In short, peptides were separated on a reversed-phase LC
Packings PepMap C18 column (0.300×150 mm) at a flow
rate 10 μL/min with a linear gradient from 0 to 65 % aceto-
nitrile in 0.06 % aqueous formic acid over a period of 55 min
using LC Packing Ultimate Chromatograph (Dionex). LC-
MS experiments were performed in a data-dependent acqui-
sition manner using Xcalibur 2.0 software (Thermo Scientif-
ic). Five most intensive precursor ions in a survey MS1 mass
spectrum acquired over a mass range of 300–2000 m/z were
selected and fragmented in the linear ion trap by collision-
induced dissociation. The ion selection threshold was 500
counts. The MS/MS spectra obtained were analyzed with
the software MassMatrix (27–30). MassMatrix was used to
generate the theoretical fragment tables of the b and y ions of
the different oxidized and cross-linked products. The theoret-
ical fragments were compared to the experimental MS/MS
spectra to validate the structures, which were taken into con-
sideration only if the difference between the theoretical and
the experimental m/z of the parent ion (and the fragment
ions) was strictly below 0.1 Da. The SYNAPT-G2 instrument
was operated for maximum resolution with all lenses opti-
mized on the [M+2 H]2+ ion from the [Glu]1-fibrinopeptide
B. The cone voltage was 30 V and Ar was admitted to the
collision cell. The spectra were acquired using a mass range of
50–2000 m/z. The data were accumulated for 0.7 s per cycle.
The CID data, at the MS2 level, acquired with the FT-ICR
instrument were obtained after an attenuation of the parent
ion of 35 %. The mass window to collect the parent ion was
fixed to 0.1 Da. Deconvolution of the electrospray ionization
data of the undigested insulin was obtained using the maxi-
mum entropy distribution algorithm implemented in theMas-
slynx MaxEnt software (Waters Corporation, Milford, MA)
using an adduct of 1 proton. Assuming a normal statistical
distribution of the noise, a uniform Gaussian with a width at
half height of 0.5 Dawas used. A number of fifty iterations and
a range between 0–36000 Da were used to build the most
probable mass spectrum of the parent ions.
RESULTS
To guide the reader through the results, these will be pre-
sented in three sections: 1) Aggregation Profile of Oxidized
Insulin and Elucidation of Aggregation Mechanism, 2) MS
Analysis of Undigested Insulin Samples, and 3) Identification
of Chemical Modifications by MS/MS Analysis of Reduced,
Alkylated, ABS-Derivatized and Digested Samples.
Aggregation Profile of Oxidized Insulin
and Elucidation of Aggregation Mechanism
Investigation of the chemical mechanisms, as well as the
aggregation profile, was achieved with SEC. This technique
was employed for several purposes: to detect and quantify
the percentage of monomer loss, and the formation of
covalent dimers and high-molecular-weight oligomers
(HMWO) during MCO, by using UV detection at 276 nm
(note that the composition of the mobile phase does not
allow us to estimate the amount of non-covalent aggregates
since these will be dissociated because of the organic solvent
and the low pH of the eluent (31)); to monitor Tyr fluores-
cence in oxidized insulin, by using an excitation wavelength
of 275 nm with emission set at 302 nm, and to detect the
development of DOPA and DOCH through derivatization
with ABS. Furthermore, we used SEC to monitor the pres-
ence of fragments after prolonged oxidation. The percen-
tages found (Table I) are in agreement with our previous
results (13). MCO under our applied standard conditions
leads to a loss of 25.6 % of monomer and the formation of
18.8 % of dimer and 6.8 % of HMWO (Fig. 2a). The
derivatization with ABS, followed by SEC analysis, allowed
the detection of DOPA and DOCH, in the monomer, as
well as in the aggregates (Fig. 2b). The overall results point
to the presence of Tyr and Phe oxidation products in all
insulin species formed during MCO. A much weaker overall
fluorescent signal was detected for the derivatized non-
oxidized insulin (Fig. 2b), suggesting that a low percentage
of DOPA was already present in the starting material, which
could have been oxidized during production, storage and
handling. The fluorescence spectra of the ABS derivatized
samples (data not shown) were in agreement with the fluo-
rescence detection performed with SEC: a low but measur-
able fluorescence emission was found for the native insulin
derivatized with ABS and a 6-fold higher fluorescence signal
was obtained for the oxidized insulin derivatized with ABS.
Aggregated insulin was almost completely absent when
MCO was performed at pH 3.0 (Fig. 2c). This result sug-
gests that the aggregation process, which appears to be
mediated by nucleophilic reactions with DOCH, is inhibited
at lower pH, likely due to protonation of free amino groups
and His residues. Nevertheless, DOPA and DOCH were
detected after derivatization with ABS (Fig. 2d), indicating
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that the lower pH did not inhibit insulin oxidation. Hence, it
may be possible that insulin oxidized at pH 3.0 would still
aggregate if the pH is increased after oxidation. To test this
hypothesis, the buffer of the insulin sample oxidized at pH
3.0 was subsequently exchanged with 50 mM sodium phos-
phate buffer, pH 7.4, using centrifugal filter units. The
sample was left to equilibrate for 12 h at room temperature
before SEC analysis. Figure 2e and Table I represent the
chromatograms and the percentages of aggregates for this
experiment, displaying an increased amount of insulin di-
mer and trimer after the buffer change. Altogether these
results indicate that Michael addition, the addition of a
nucleophile to an α,β-unsaturated carbonyl compound
(32), may be the main mechanism of covalent insulin aggre-
gation during MCO. Moreover, this experiment disproves a
major role of S-S scrambling in insulin aggregation during
MCO. However, the occurrence of non-covalent (besides co-
valent) aggregation cannot be fully excluded.
Additional evidence for Michael addition was provided
in an experiment in which we performed the oxidation of
insulin at pH 8.0, in the presence of a relatively high con-
centration (0.25 M) of ammonium bicarbonate. Under these
conditions ammonia competes with nucleophilic functional
groups of insulin (i.e. the N-terminus of Gly A1 and Phe B1,
and the side chains of His B5, B10 and Lys B29) for the
addition to DOCH, thereby inhibiting aggregates formation,
as shown in Fig. 3a and indicated by the low percentages of
covalent aggregates measured (Table I). This was confirmed
with FT-ICR MS analysis, performed on oxidized insulin
in ABI, after reduction, alkylation and Glu-C digestion.
As can be seen in the chemical structure representatively
depicted in Fig. 3b, two amino groups (highlighted in
blue) are covalently bound to the first Phe residue and
one amino group is covalently bound to the second Phe
residue, indicating that Michael addition occurred be-
tween both oxidized Phe residues and ammonia originat-
ing from the buffer. These Michael addition products are
generated by addition of the nucleophiles to the two β-
type carbon atoms in the oxidation product DOCH, and
are consistent with the mass increases of the respective
original Phe residues; however, due to the low abundance
of sample we did not confirm the regiochemistry of nu-
cleophile addition by NMR. The most relevant ions in the
MS/MS spectra, which allow to confirm the addition of
ammonia to DOCH, are b5+, y6++ and y5+. The first,
with m/z 711.31 of a singly charged ion, shows the
sequence GB23FFYTB27 plus the additional molecular
weight of three oxygen atoms and three ammonia mol-
ecules. These data suggest that the sequence PKT is
neither oxidized, nor derivatized with amino groups.
The doubly charged ion y6++, with m/z 394.6, related
to the sequence FB25YTPKTB30, shows that one oxygen
and one ammonia molecule are incorporated into this
sequence. Of course the Tyr residue could be the target for
this incorporation; however, the ion y5+ argues against this
hypothesis where the singly charged ion with m/z 609.32
represents the unmodified sequence YB26TPKTB30.
To evaluate the potential of MCO to induce fragmenta-
tion, already reported by other authors for the MCO of
glycated insulin (9,33), and by our group for the MCO of
PEGylated insulin (13), human insulin was oxidized in
50 mM PB, pH 7.4, for 24 h at room temperature and
37°C. Figure 2f clearly shows the elution of species after the
monomer peak, which indicates the formation of lower mo-
lecular weight species.
MS Analysis of Undigested Insulin Samples
The FT-ICR MS analysis presented in this section was per-
formed on oxidized insulin and native insulin (our control),
prior to reduction, alkylation, ABS-derivatization and diges-
tion with Glu-C. This analysis was executed to monitor the
formation of oxidized monomers and to confirm the MCO-
induced fragmentation, as well as to quantify these species
relative to native insulin.
Oxidation
Human insulin contains three Phe and four Tyr residues. Ox-
idation of Phe toDOPAwould require the incorporation of two
Table I Percentages of Monomer, Dimer and High-Molecular-Weight Oligomers (HMWO) for the Insulin Oxidized Under Different Conditions and
Native Insulin
Sample %Monomer %Dimer %HMWO
Oxidized insulin in PB, pH 7.4 74.4±0.9 18.8±1.4 6.8±1.2
Oxidized insulin in ABI, pH 8.0 96.1±0.7 3.9±0.7 NDa
Oxidized insulin in sodium citrate, pH 3 99.2±0.3 0.8±0.3 ND
Oxidized insulin in sodium citrate, pH 3.0, spiked into PB, pH 7.4 88.8±1.3 9.3±1.1 1.9±0.1
Native insulin in PB, pH 7.4 99.4±0.2 0.6±0.2 ND
Based on SEC analysis with UV detection at 276 nm; data represent mean±standard deviation of 3 individual batches
aND0not detected
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oxygen atoms. Instead, oxidation of Tyr to DOPA would be
represented by the incorporation of one oxygen atom. Hence, it
should be possible to detect mass increases corresponding to ten
atoms of oxygen permonomer, consideringDOPA as oxidation
product of Phe and Tyr. Based on this number, after deconvo-
luting each MS spectrum by using the maximum entropy
distribution algorithm (Fig. 4), we added up the intensities
observed for all monomers containing additional oxygen atoms
(n00-10) (i.e., for the masses 5,804.63+16, 5804.63+32+…+
5,804.63+160 Da). The resulting intensity of oxidized mono-
mer in insulin exposed to MCO was found to be ~300 fold
higher than that in non-oxidized insulin (Fig. 5), suggesting that
the amount of insulin monomer containing oxygen had in-
creased dramatically after MCO. These calculations are
possible because after deconvolution of the mass-to-charge ra-
tios, the absolute intensity of each ion is conserved. For better
clarity, the oxidized monomer in insulin exposed to MCO and
that of the non-oxidized insulin are presented in the mass range
5,805-5,961 (Fig. 4a, b). Figure 4a shows that the intensity of the
mass signal at 5820.62 Da (indicating incorporation of one
oxygen atom) and the intensity of the mass signal at
5852.61 Da (indicating incorporation of three oxygen atoms)
are much more intense after oxidation. Note that signals indi-
cating incorporation of several other numbers of oxygen atoms
were detected too, although with lower intensity. Although MS
analysis cannot detail which amino acid is exactly oxidized, our
calculation provides a first estimation for the extent of MCO in
the insulin monomer.
Fig. 2 SEC with intrinsic tyrosine fluorescence detection (a, c, e, f; Ex 275 nm-Em 302 nm) and ABS fluorescence detection (b, d): (a) insulin oxidized in
PB 50 mM, pH 7.4, for 3 h at room temperature (in red) and its control, untreated insulin (in blue); (b) oxidized insulin (pH 7.4), derivatized with ABS (in
red) and its control, untreated insulin derivatized with ABS (in blue); (c) insulin oxidized in 50 mM sodium citrate, pH 3.0, for 3 h at room temperature (in
red) and its control, untreated insulin (in blue); (d) oxidized insulin (pH 3.0), derivatized with ABS (in red) and its control, untreated insulin derivatized with
ABS (in blue); (e) insulin oxidized in 50 mM sodium citrate, pH 3.0, for 3 h at room temperature, exchanged in 50 mM PB, pH 7.4, for 12 h at room
temperature (in red) and its control, oxidized insulin (pH 3) (in blue); (f) insulin oxidized in 50 mM PB, pH 7.4, for 24 h, at room temperature (dotted red
line) and at 37°C (solid red line), untreated insulin (blue line).
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Fragmentation
In order to detect and quantify the yield of insulin fragments
relative to native insulin and to understand if fragmentation,
measured by SEC, occurred during sample preparation for
analysis (reduction, alkylation, ABS-derivatization and di-
gestion) or prior to sample preparation, i.e. during the
exposure of insulin to Cu2+ and L-ascorbate, MS analysis
of native and oxidized insulin was performed prior to and
after reduction, alkylation, ABS-derivatization and diges-
tion. Figure 4c and d represent a zoom (16X) into the mass
region between 100 and 5805 Da: clearly the oxidized
insulin contains new peptides of a lower molecular weight
compared to insulin. We processed the MS spectra of oxi-
dized and non-oxidized insulin as follows: 1) deconvolution
using the maximum entropy distribution algorithm; 2) sum
of the intensities of all the fragments with a molecular weight
between that of glycine (the smallest amino acid in insulin)
and the molecular weight measured for insulin (i.e.
5804.63 Da) minus the molecular weight of glycine, after






j ¼ Mw Glyð Þ ¼ 75:03
k ¼ MwðInsulin  Glyþ H2OÞ
k ¼ 5804:63 75:03þ 18





The MS spectra of the oxidized and native insulin
that were used for this calculation are displayed in
Fig. 4c and d, respectively. Figure 5 represents the histo-
grams plotted using the intensity values of the same
spectra. The total intensity of the control (i.e. native
insulin), was calculated between masses of 0 Da and
Fig. 3 (a) SEC with intrinsic
tyrosine fluorescence detection
(Ex 275 nm-Em 302 nm) of in-
sulin oxidized for 3 h at room
temperature in ABI 0.25 M (in
red) and its control (in blue). (b)
MS/MS of peptidic fragment
obtained from oxidized insulin in
ABI 0.25 M, reduced (DTT),
alkylated (IAM), and digested with
Glu-C. The amino groups added
through Michael addition to
the oxidized phenylalanine are
highlighted in blue.
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36,000 Da, i.e. until just beyond the theoretical molecu-
lar weight of the insulin hexamer. Based on this calcula-
tion, the total yield of fragments in the non-oxidized
control was 0.3 % compared to 3.1 % in insulin exposed
to Cu2+ and L-ascorbate (percentages have been calcu-
lated dividing the total intensity of the fragments over
the total intensity of the native insulin used as a control).
For a better view of the fragments, we provide a zoom of
the range between 100–5,805 Da of native insulin and
oxidized insulin (Fig. 4c, d). Altogether these results
suggest that MCO induces peptidic fragmentation. We
did not explore in more detail the mechanism(s) by
which such fragmentation occurs, nor did we search for
all the possible cross-link in which the new N-termini
could be involved. However, we did note the generation
of new cross-links between insulin and such fragments
(see below), which contain new N-termini and C-terminal
amino acids not generated by Glu-C digestion.
Identification of Chemical Modifications by MS/MS
Analysis of Reduced, Alkylated, ABS-Derivatized
and Digested Samples
The FT-ICR MS analysis of oxidized and native insulin (con-
trol) was performed after reduction, alkylation, ABS-
derivatization and digestion with Glu-C, by injecting the sam-
ples into themass spectrometer by liquid chromatography. The
aim of this analysis was to map the chemical modifications in
the primary structure of insulin, to identify the nonreducible
cross-links involved in insulin aggregation and to identify the
fragments. Because different kind of oxidized, ABS-derivatized,
and non-oxidized fragments were found, we hereafter define
“fragments” as peptides resulting from at least one cleavage site
that differs from the one expected from proteolytic digestion by
Glu-C (i.e. after glutamic acid; Glu; E) and we define “Glu-C
fragments” as peptides originating from the expected proteo-
lytic cleavage sites of Glu-C. Table II lists all the detected “Glu-
Fig. 4 Mass spectrum (MS) of undigested insulin and undigested insulin oxidized for 3 h at room temperature in 50 mM PB, pH 7.4. Spectra
are shown for oxidized insulin (a, c) and native insulin (b, d) in the mass range 5805–5961 to show the oxidized monomer (a, b) and in the
mass range 100–5805 to show the fragments (c, d). Spectra were obtained using the maximum entropy distribution algorithm implemented in
the Masslynx MaxEnt software (Waters Corporation, Milford, MA) using an adduct of 1 proton. (Please note that 5804.63 represents the molecular mass of
unprotonated insulin.)
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C fragments” (oxidized and ABS-derivatized) and “fragments”
(oxidized, ABS-derivatized and non-oxidized). Non-oxidized
Glu-C fragments were measured for both oxidized and native
insulin but are not listed in Table II, since their presence was
expected and represents the majority of Glu-C fragments.MS/
MS spectra of non-oxidized fragments (available in the supple-
mentary material) are only briefly discussed in this manuscript,
because the main focus of our work was to elucidate the
chemical mechanisms of insulin aggregation during MCO. As
displayed in Table II, the following section is divided into the
following subsections: Oxidized Glu-C Fragments, ABS-
Derivatized Glu-C Fragments, Oxidized Fragments, ABS-
Derivatized Fragments, Non-oxidized Fragments. Regarding
the description of these fragments, the prefixes and subscripts A
and B refer to sequences from the A and B chain, respectively,
while b and y refer to the cleavage sites according to the
nomenclature introduced by Roepstorff (34).
Oxidized Glu-C Fragments
RB22GFF*Y*TPKTB30. The C-terminal region of chain B con-
tains two Phe and one Tyr in positions B24, B25 and B26,
respectively. DOPA and DOCH can arise from the oxidation
of all these residues. Thus it becomes of primary importance to
identify the ions, which allows us to discriminate between
different oxidation products. The MS/MS spectra reported
in supplementary Fig. S1A provides evidence for the oxidation
of Phe B25 to Tyr where * indicates the incorporation of one
oxygen atom. The ion b3+, despite its low intensity, indicates
that Phe B24 is present in the native, non-oxidized state, where
m/z 361.2 corresponds to the singly charged ion of the se-
quence RGF. Instead, the ion b4+ provides evidence for oxi-
dation of Phe B25. A careful analysis of the spectra (Figures
S1B) reveals the contemporary presence of two different y5+
ions, indicated as (F4)y5+ with m/z 625.5 (which corresponds
to a structure containing Tyr B26 oxidized) and, (HO-F4)y5+
with m/z 609.4 (which corresponds to a structure contain-
ing Phe B25 oxidized). Panel C shows the b4+ ions for
these two coexisting structures, again representing oxida-
tion of Phe B25 or Tyr B26, respectively. Hence, both Phe
B25 and Tyr B26 are targets for the incorporation of one
oxygen atom.
AB14LY*LVCGEB21. Supplementary Figure S2 displays the
MS/MS data for the peptide ALY*LVCGE, which contains
an expected Glu-C cleavage site, where Y* represents the
incorporation of one oxygen into Tyr, i.e. the formation of
DOPA (the Cys residue is alkylated with IAM). This product
is confirmed through the presence of the ions b3+-b5+
(although b3+ and b4+ show low intensities) and y5+. The
singly charged ions b3+, b4+ and b5+ indicate that the oxygen
is in one of the following sequences: ALY, ALYL, or ALYLV.
The singly charged ion y5+ indicates that the sequence
LVCGE is not oxidized. Therefore, oxygen incorporation
must have occurred on one of the first three amino acids,
ALY, where Tyr represents the most oxidation-sensitive target
amino acid. Further evidence for Tyr B16 oxidation through
ABS derivatization is given below.
F*B1VNQHLCGSHLVEB13. TheN-terminus of chain B, Phe B1,
displays a mass increase consistent with the oxidation of Phe B1
to cyclohexadienone. The MS/MS analysis (Figure S3) of the
sequence F*VNQHLCGSHLVE indicates the formal addition
of one oxygen atom and loss of 2 hydrogens from Phe B1, i.e. a
mass increase of 14Da through the appearance of the following
ions: y9+, which suggests that the sequence HLCGSHLVE is
not oxidized, and b6+, indicating the oxidation of the sequence
FVNQHL. In this sequence, HL can be excluded as an oxida-
tion target because of the nature of y9+. Since in the sequence
FVNQ, F is most sensitive to oxidation we conclude that
oxidation targets Phe B1.
F**B1VNQHLCGSHLVEALYLVCGEB21. Phe B1 can be fur-
ther oxidized to DOCH (Figure S4). The observed
masses of the ions y17++-H2O and y17
+ exclude any
oxidation of other amino acids sensitive to oxidation in
F**B1VNQHLCGSHLVEALYLVCGEB21. The ion y17
+
with m/z 1899.82 shows an intensity which is about
80 % of that of b16+ with m/z 1898.75; thus, it should not
be considered the first isotope peak of b16+, which would be





tary Figure S5 shows that Tyr B26 is converted to DOPA
and/or DOCH, indicated by derivatization with one mole-
cule of ABS (indicated with the symbol #). The ions with m/z
Fig. 5 Plot representing the intensity of fragments and oxidized monomer
relative to the total intensity of all detected peaks for native insulin (control, in
blue) and insulin oxidized for 3 h at room temperature in 50mM PB, pH 7.4 (in
red). Data are derived from the spectra reported in Fig. 4.
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361.28 and m/z 508.26, corresponding to b3+ and b4+,
respectively, suggest that both Phe B24 and Phe B25 are not
oxidized in this sequence. If for instance, Phe B24 (in the
sequence RGFB24FYTPKT) had been oxidized, the b3
+ ion
would have been expected with m/z 377.28 (i.e. 361.28+
16 Da). Instead, the ions b5+ and b6+ provide evidence that
Tyr B26 is the target of oxidation. For additional evidence,
supplementary Figure S6 displays the MS/MS spectrum of
RGFFY##TPKT, derivatized with two molecules of ABS, as
shown in the displayed structure. Here, the ions b3+ and b4+
are identical to the ones reported in Figure S5, although more
intense. The ion with m/z 1037.29 corresponding to the ions
b5+ and y5+ reported in the inset of Figure S6, confirm that
the original Tyr contains two ABSmolecules. We had realized
in the past (19,20), that derivatization with ABS can lead
to the incorporation of one or two molecules of ABS into
the final benzoxazole product (see scheme 1), depending
on the availability of ammonia, resulting in competition of
ammonia and ABS for the 6-position in benzoxazole. In
addition to that, it seems that the competition between
ammonia and ABS depends on the steric hindrance of the
peptide which is derivatized: i.e., derivatization with two
ABS molecules of sterically less accessible DOPA and
DOCH can be kinetically less favorable than that of more
exposed residues. It must be noticed that the sequence
RB22GFFYTPKTB30, depicted in Figures S5 and S6, does
not necessarily belong to the same B chain: in other
words, the sequence derivatized with one ABS molecule
could be involved in the formation of HMWO, while the
doubly ABS-derivatized sequence can actually be present
in the monomer as well, although oxidized, and subse-
quently be derivatized with two ABS molecules.
Oxidized Fragments
F*B1VNQHLCGB8. Phe B1 is oxidized to hydroxylated
Phe, indicated through the MS/MS data displayed in
Figure S7: the ion y7+ shows that none of the amino
acids in the sequence C-terminal to Phe B1, VNQHLCG, is
oxidized. Therefore, the ion b5+ confirms oxidation of
Phe B1. In fact, Phe hydroxylation can occur in positions
ortho, meta and para; however, only the latter would lead
to Tyr.
EB21RGF**FYTPKTB30. The MS/MS data displayed in Fig-
ure S8 are consistent with the oxidation of Phe B24 to
DOCH. The ions b4+ and y6+ are fundamental to confirm
the oxidation of Phe B24 since the first indicates the pres-
ence of the sequence ERGF**, and the second, suggests that
the sequence FYTPKT is not oxidized. Further confirma-
tion of the chemical structure in which Phe B24 is doubly
oxidized arises from the detection of the internal fragment
GF**FY with m/z 545.39, which can be produced during
the analysis via specific pathways consistent with the mobile
proton model (35).
F*B1VNQHLCGSHLVEALB15. Phe B1 oxidation is also evident
in the sequence F*VNQHLCGSHLVEAL, indicated by the
MS/MS data displayed in Figure S9. Here it is sufficient
to consider the ions y13+ and b14++. The ion y13+
indicates that the sequence NQHLCGS is not modified.
On the other hand b14++ indicates oxidation in the
sequence FVNQHLCGSHLVEA. By exclusion, this limits
oxidation to the N-terminal subsequence FV, where F repre-
sents the most oxidation-sensitive amino acid.
ABS-Derivatized Fragments
AB14LY
#LVC B19. We further corroborated the formation of
DOPA through derivatization of the oxidized peptide
ALY*LVC with ABS (Figure S10). The only possible site
for derivatization in this peptide is an oxidized Tyr residue,
since ABS derivatization requires the presence of DOPA




##QLE A17. The MS spectra
presented in Figures S11 and S12 provide evidence for
the ABS derivatization of Tyr A14 within the sequence
SLYQLE. Successful derivatization with one and two
molecules of ABS indicates oxidation of Tyr A14 to
either DOPA or DOCH. In both figures the ions b3+
with m/z 560.11 and 730.07, respectively and, the ion
y4+ with m/z 748.39 and 918.15, respectively, indicate
derivatization of the original Tyr residue with one and
two molecules of ABS.
Non-oxidized Fragments
Two types of non-oxidized fragments were detected in the
control (Table II). They are likely generated during production
or storage as a consequence of low traces of transition metals.
Instead, 14 non-oxidized fragments were detected as a result of
MCO, summarized in the last column of Table II. The MS/
MS data of all these fragments are reported in the Supplemen-
tary Material (Figures S13-S27).
Covalent Cross-Links
This section focuses on the identification of covalent cross-
links by MS/MS analysis. Figure 6 summarizes all the
covalent cross-links detected as a result of the MCO of
insulin.
Gly A1 –Tyr A14 Cross-Link. Figure 7a displays the MS/MS
data consistent with a cross-link betweenGly A1 and Tyr A14.
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The ions Bb1+, By3+ and Ab3+ are the most relevant ones to
confirm the cross-link between Gly A1 and Tyr A14. In
particular Bb1+ shows that the sequence ICSLY is covalently
attached to Gly. The ion By3+ indicates that the sequence
IVE is not involved in the cross-link and, therefore, can be
dissociated during theMS/MS analysis since it is connected to
Gly A1 only through a peptide bond (36). Finally, the ion
Ab3+ provides evidence that ICS is not involved in the cross-
link. In the structure provided in Fig. 7a, the covalent attach-
ment of Gly A1 to Tyr A14 is representatively shown for the 6
position of the original DOPA (or DOCH) product. While, in
principle, Michael addition is possible also at positions 1 and
2, position 6 is sterically less hindered, and that is why we
selected to represent the adduct formation at position 6.
However, we have currently no evidence for this regioselec-
tivity. Further confirmation of the structure reported in Fig. 7a
was obtained through the spectrum displayed in Fig. 7b,
where the ion M+-H2O was detected.
Gly A1—Tyr B 26 Cross-Link. Figure 7c represents the cross-
link of Gly A1 of the sequence GIVE to Tyr B26. The mass
spectra displayed in Fig. 7c represents sodium adducts of the
respective peptide fragment(s), likely due to incomplete re-
moval of buffer during dialysis. Therefore, all the m/z of the
ions presented in Fig. 7c have an increasedmass of 23Da. The
ion [By2+Na]+, representing the singly charged sequence
Fig. 6 Identified inter-/intra-molecular cross-links measured after MCO of insulin, between (a) Gly A1-Tyr A14, (b, c) Gly A1-Tyr B26, (d) Gly A1-Tyr B16,
(e) Phe B1-Tyr A14, (f) His B10-Tyr B16, (g) His B5-Tyr A19, (h) Lys B29-Tyr A14. In blue are shown the amino acids with nucleophilic properties and in red
the amino acids oxidized to DOCH, which are Michael acceptor for nucleophilic addition. Further details are given in Fig. 7 and in the main text in the
section “Covalent Cross-Links”.
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VE, suggests that the amino acids Val and Glu are not
involved in the new covalent bond. If this sequence had been
involved in the new covalent bond with Tyr, it would not have
been possible to detect the ion [By2+Na]+, since only disso-
ciation of peptide bonds occurs during the low energy collision
with the inert gas. [Bb2+Na]+ indicates that the sequence GI
is covalently bound to the sequence FFY. We excluded the
possibility of DOPA as the product of one of the Phe residues,
since in such case the ion [Bb2+Na]+ would have a mass
increase (relative to the expected mass of the fragment of
unmodified insulin) larger than 16 Da (the oxidation of Phe
toDOPA andDOCH requires two oxygen atoms); if one of the
Phe residues were exclusively oxidized to Tyr, the ion [Bb2+
Na]+ would have the same molecular weight as the one
detected in this MS/MS spectrum. In such case, however, it
would not be possible to observe Michael addition, since the
new Tyr residue (generated from the mono-oxidation of Phe) is
not a Michael acceptor unless it is further oxidized to quinone.
In Fig. 7d the original sequence FFY shows additional
oxidation of both Phe residues (in contrast to Fig. 7c, which
shows the native Phe residues in FFY): one of them to
DOPA and the second one to a 6-amino substituted DOPA,
likely originating from Michael addition of ammonia to a
DOPA oxidation product. The ions By1+, with m/z 612.22,
displayed in the inset, and Ab1+, with m/z 626.29, unequiv-
ocally indicate that the covalent bond is between Gly and
Tyr: By1+ represents the singly charged sequence Y-GIVE
and Ab1+ corresponds to the singly charged sequence FFY-
G. The combination of both demonstrates that the new
covalent bond, not dissociable during MS/MS analysis, is
located between Tyr and Gly. Importantly, our results show
that predominantly Tyr oxidation products serve as Michael
acceptors for cross-link formation during the MCO of insu-
lin (see also below). There are several possible rationales for
this behavior, including protein conformation and the re-
spective yields of Tyr and Phe oxidation products: the
Fig. 7 MS/MS of (a, b) sequence GIVE cross-linked through the glycine A1 to the sequence ICSLY, (c) sequence GIVE cross-linked through the glycine A1
to the sequence FFYT, (d) sequence GIVE cross-linked through the glycine A1 to the sequence FFY, (e) sequence GI cross-linked through the glycine A1 to
the sequence LYLVCGE, (f) sequence FVNQ cross-linked through the phenylalanine B1 to the sequence LYQL, (g) sequence SH cross-linked through the
histidine B10 to the sequence YLVCG, (h) sequence HLCGS cross-linked through the histidine B5 to the sequence YCN, (i) sequence PK cross-linked
through the lysine B29 to the sequence YQLE. The fragments have been obtained after reduction (DTT), alkylation (IAM), ABS-derivatization and digestion
(Glu-C) of oxidized insulin. Further explanation can be found in the text.
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oxidation of Phe to DOCH requires one additional
oxidation step compared with that of Tyr to DOCH,
suggesting that DOCH formation from Tyr is kinetically
favorable.
Gly A1—Tyr B16 Cross-Link. Figure 7e displays MS/MS data
consistent with a covalent cross-link between Gly A1 and
Tyr B16. The most relevant ion in this figure is Ab2+ with
m/z 479.27, which demonstrates that the sequence GI is
Fig. 7 (continued).
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covalently bound to LY. Since Ile and Leu do not contain
functional groups amenable to Michael addition, we con-
clude that the covalent bond is formed between Gly and
Tyr.
Phe B1—Tyr A14 Cross-Link. Phe B1 is not only a possible
target for oxidation; the free N-terminal amino group can
react via Michael addition with DOCH. The spectrum
depicted in Fig. 7f shows the relevant ions consistent with
a cross-link between Phe B1 and Tyr A14: Ab1+ with m/z
697.36 shows the existence of a peptide containing the
following amino acids: Phe, Tyr, Gln and two Leu, plus
the molecular weight of one oxygen atom. However consid-
ering only the ion Ab1+, it is not possible to localize the
oxygen addition and to characterize the nature of the cross-
link. The ion Bb2+, with m/z 797.36, indicates that the
sequence FVNQ is connected to the sequence LY. The
ion Ay3+ -NH3, with m/z 343.16, excludes any covalent
cross-link of the sequence VNQ. In the sequence LY only
Tyr oxidation can lead to a Michael acceptor for the amino
terminal of Phe B1, which suggests a cross-link such as
depicted in Fig. 7f.
His B10—Tyr B16 Cross-Link. Figure 7g displays a cross-link
between His B10 of the sequence SH and Tyr B16 of the
sequence YLVCG. The relevant ions in this spectrum are
Ab1+ and Ay4+. Ion Ab1+, with m/z 420.14, suggests that
the sequence SH is covalently bound to the original Tyr
residue (after oxidation of Tyr to DOCH). The deproto-
nated imidazole nitrogen of His is an appropriate nucleo-
phile for Michael addition, demonstrated for example for
His addition to dehydroalanine (36).
His B5—Tyr A19 Cross-Link. Figure 7h displays a cross-link
between His B5 of the sequence HLCGS and Tyr B16 of
the sequence YCN and the MS/MS data supporting this
assignment. We note that the ion Ab1+-NH3 shows an
intensity which is about 80 % of that of Ab1-H2O. Thus,
the ion with m/z 533.14 should not be considered the second
isotope of Ab1+-H2O, suggesting that the N-terminal amino
group of the His is free and not involved in the new covalent
bond.
Lys B29—Tyr A14 Cross-Link. Figure 7i represents the cross-
link between Lys B29 and Tyr A14. The relevant ion in the
spectra is Ab1+, since it localizes the cross-link to Tyr and
the amino acids Pro and Lys in the sequence PK. Because
the MS/MS data in Fig. 7i shows no B ions, we cannot
conclude whether the cross-link involves the side chain amino
group of Lys or the amino group of Pro. The latter would
require that non-oxidative fragmentation between Thr B27
and Pro B28 occurs prior to cross-linking; the side chain
amino group of Lys B29 represents a good nucleophile and
it can therefore be assumed that at least some of the cross-links
are formed through the reaction of Tyr A14 with Lys B29.
DISCUSSION
We performed a detailed mass spectrometric analysis of insu-
lin in order to elucidate the mechanisms and amino acid
residues involved in MCO and MCO-mediated aggregation.
The oxidation of Phe and Tyr leads to the formation of
catechol structures that can be further oxidized to DOCH.
These oxidation products serve asMichael acceptors for cross-
links with several nucleophiles present in the insulin sequence.
Formation of dityrosine, as a potential structure involved in
the cross-linking of insulin, was not detected, neither with
fluorescence measurement (see material and methods), nor
with the help of MassMatrix software. This is not surprising
since it has been reported that only the hydrogen peroxide/
copper system is capable of inducing dityrosine formation (37).
Schiff base formation could potentially be in competition with
Michael addition, nonetheless such cross-links can be reversed
relatively easily and based on our results does not appear to be
the main mechanism of insulin aggregation. Changes in the
primary structure, as reported in this paper, may alter the
biological activity of insulin with severe consequences on the
glycemic control. Furthermore, changes in the secondary,
tertiary and quaternary structure as a consequence of oxida-
tion, as reported by us before (13), may generate new repet-
itive epitopes or open the access to hidden epitopes that could
contribute to the formation of immunogenic products.
In addition to the characterization and localization of
oxidation products, we provided quantitative data on the
amount of fragments and oxidized monomers. An important
feature of insulin exposed to MCO is the appearance of frag-
ments, which increases the number of polypeptide nucleo-
philes available for Michael addition. At this point, we do
not know whether the observed insulin fragmentation pre-
cedes or follows cross-link formation. Furthermore, it is un-
known whether Glu-C might have a different specificity
towards oxidized protein. The actual mechanism of cleavage
is currently unknown, but we can exclude the classical oxida-
tive cleavage (38) since we did not detect the α,β-dicarbonyl
products expected for such a mechanism. Instead, all non-
specific cleavages appear to involve a hydrolytic cleavage of
the respective peptide bonds. It may be possible that the
addition of Cu2+ and L-ascorbate promote the formation of
peptide-metal complexes with hydrolytic activity, such as de-
scribed for the cleavage of amides through Cu2+ (39). Surpris-
ingly, most of the non-specific peptide fragments we detected
were already reported by other authors, e.g. after the oxida-
tion of glycated insulin by Fenton chemistry (9,33); however,
Guedes et al.(33) interpreted the cleavage mechanism as
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oxidative cleavage, which is inconsistent with the intact C- and
N-termini of the detected peptide fragments.
Through MCO experiments at various pH, and in the
presence of ammonia, we are able to confirm that Michael
addition between insulin chains causes covalent aggregation. In
the presence of ammonia, which competes for Michael addi-
tion to DOCH, aggregation was almost completely inhibited.
Although such experimental conditions allow to prevent aggre-
gation, we noted that the introduction of an amino group on
oxidized Tyr or Phe might still have consequences for the
immunogenicity of this small polypeptide hormone.
Several proteins have been shown to form aggregates after
exposure to Cu2+/L-ascorbic acid, such as recombinant SHa
(29–231) prion protein (40), superoxide dismutase (41), mono-
clonal IgG2 (42), interferon alpha 2a (5,6) and interferon beta
1a (7). The results presented in this paper may serve as a
model to rationalize the chemical mechanisms of aggregation
during MCO of proteins in general. Although insulin lacks
Trp and Met, which are also prone to oxidation (43,44) and
are present in most other proteins, DOPA and DOCH should
not be formed from oxidation of Trp orMet, thus they cannot
act as electron acceptor forMichael addition. SinceMCOwas
performed at pH 7.4, where insulin is present mainly in the
hexameric state (45), the cross-links we measured are likely to
be intermolecular cross-links, i.e. formed between different
insulin molecules. As an example we calculated the distance
of Gly A1 and Tyr A14 and Gly A1 and Tyr A19 within the
same A-chain (using Swiss pdb viewer (46,47) and T6 human
insulin at 1.0 Å resolution, 1MSO pdb file). An average of
18.5 Å was measured for a theoretical covalent bond between
the amino group of Gly A1 and the carbon in ortho of the
aromatic ring of Tyr A14, and an average of 8.3 Å for the
amino group of Gly A1 and the carbon in ortho of the
aromatic ring of Tyr A19, which seems to be too far for an
intramolecular reaction (e.g., the length of the peptidic bond
between Gly A1 and Leu A2 is 1.3 Å). We also noticed that
Phe residues, oxidized to DOCH, were not involved in cross-
links, nor were they derivatized with ABS. In both cases this
could be due to low accessibility of Phe residues which might
belong to chains B involved in the formation of HMWO, in
which only DOCH originated from Tyr is accessible for ABS
derivatization. Moreover, in the case of cross-links it could be
speculated that the oxidation of Tyr to DOCH (which
requires the addition of only one oxygen atom), is kinetically
favorable over the oxidation of Phe to DOCH (which requires
two oxidation steps). This can potentially lead to a depletion of
the nucleophiles available in the insulin molecule.
CONCLUSIONS
Oxidation is one important degradation process that pro-
teins can undergo. In this work we highlighted the potential
consequences of DOPA and DOCH formation and also
illustrated how the knowledge of oxidation mechanisms
can be utilized to investigate the mechanism of covalent
aggregation. To this end, recombinant human insulin was
used as a model: oxidation of aromatic amino acids residues,
besides others, leads to α,β unsaturated carbonyl com-
pounds, which are electron acceptors for Michael addition.
These reactive groups, resulting from oxidation, not only
can lead to covalent protein aggregation, as shown for
insulin in this paper, but also may lead to cross-links be-
tween protein molecules and amino acids, which are typi-
cally present during cell culture and are often used as
formulation excipients. This must be taken into consider-
ation during production and formulation development of
therapeutic proteins.
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